Corcept Therapeutics (CORT) Tmuɣli n wazal
Corcept Therapeutics
Ṛṛbem n lḥedd$116.12Yettwalemmaḍ 25 Sep 2026 19:59 UTC
Beddel-1.97%
Asnulfu n AI: CORT
AI tessawal ɣef timaqsiṭ n wazal i wass n tnekkit d-iteddun, taggara n yimal akked taggara n waggʷas. Asnifel yettwamḍen seg wazal aneggaru. Aya d tinineḍ n tḥisabt, ma tga ara timsisi n usihel.
Asref n 6 isggʷasn ineggura
Premium tessaɣ-d iswiyat n tɣara n AI i wass, amalas d waggʷas n yiwen i uḍris-a akk d yisɣunan niḍen.
Serreḥ Premium🔒 Tazmilt n usenfar
Amezruy n tmuɣliyin — akk tmuɣliyin n zik akked wazal n tnekkit — d akcum n Premium.
Serreḥ PremiumƔef tneɣlaft-a
Corcept Therapeutics Inc. is a pharmaceutical company engaged in the development of drugs for the treatment of serious metabolic and psychiatric disorders. The company’s main product modifies the action of cortisol, also known as the “stress hormone,” by blocking cortisol’s binding to one of two known receptors—the type 2 glucocorticoid receptor.
